Efficacy of LFF571 in a hamster model of Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4459-4462

  Trzasko, Anna ^a   Leeds, Jennifer A ^a   Praestgaard, Jens ^c   LaMarche, Matthew J ^b   McKenney, David ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Global Discovery Chemistry   (United States)

^c Translational Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; LFF 571; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HAMSTER; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CRICETINAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; MALE; MESOCRICETUS; RECURRENCE; THIAZOLES; VANCOMYCIN;

EID: 84864386615     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06355-11     Document Type: Article

References (34)

1. Anton PM, et al. 2004. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975-3979. (Pubitemid 39304630)
2. Bartlett JG. 2008. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin. Infect. Dis. 46(Suppl 1):S4-S11. (Pubitemid 351323660)
3. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. 1978. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298:531-534. (Pubitemid 8295586)
4. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. 1977. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136:701-705. (Pubitemid 8223685)
5. Bouza E, et al. 2008. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin. Microbiol. Infect. 14:S103-S104.
6. Reference deleted.
7. Chang JY, et al. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197:435-438.
8. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56:2493-2503.
9. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
10. Cornely OA, et al. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281-289.
11. Dong MY, Chang TW, Gorbach SL. 1987. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032. Antimicrob. Agents Chemother. 31:1135-1136. (Pubitemid 17099591)
12. Dvoskin S, et al. 2012. A novel agent effective against Clostridium difficile infection. Antimicrob. Agents Chemother. 56:1624-1626.
13. Dzink-Fox J, et al. 2011 Antimicrobial activity of the novel elongation factor Tu inhibitor, LFF571, abstr F1-1346. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
14. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J, Jr. 1995. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16:459-477.
15. Hecht D, Osmolski J, Gerding D. 2012. Activity of LFF571 against 103 clinical isolates of C. difficile, abstr P-1440. Abstr. 22nd Eur. Soc. Clin. Microbiol. Infect. Dis., London, United Kingdom.
16. Hogg T, Mesters JR, Hilgenfeld R. 2002. Inhibitory mechanisms of antibiotics targeting elongation factor Tu. Curr. Protein Pept. Sci. 3:121-131. (Pubitemid 34520657)
17. Kelly CP, LaMont JT. 2008. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359:1932-1940.
18. Kokkotou E, et al. 2008. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob. Agents Chemother. 52:1121-1126. (Pubitemid 351358396)
19. Kurtz CB, et al. 2001. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob. Agents Chemother. 45:2340-2347. (Pubitemid 32664476)
20. LaMarche MJ, et al. 2012. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J. Med. Chem. 55:2376-2387.
21. Leeds JA, Sachdeva M, Mullin S, Dzink-Fox J, LaMarche MJ. 2012. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob. Agents Chemother. 56:4463-4465.
22. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
23. Lowy I, et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
24. Mathur T, et al. 2011. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. J. Antimicrob. Chemother. 66:1087-1095.
25. McGlone SM, et al. 2012. The economic burden of Clostridium difficile. Clin. Microbiol. Infect. 18:282-289.
26. McVay CS, Rolfe RD. 2000. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44:2254-2258. (Pubitemid 30650864)
27. Ochsner UA, et al. 2009. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J. Antimicrob. Chemother. 63:964-971.
28. O'Neill GL, Beaman MH, Riley TV. 1991. Relapse versus reinfection with Clostridium difficile. Epidemiol. Infect. 107:627-635.
29. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186:1781-1789. (Pubitemid 35463511)
30. Selva E, et al. 1991. Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. I. Isolation and characterization. J. Antibiotics 44:693-701.
31. Swanson RN, et al. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. 35:1108-1111.
32. Swanson RN, et al. 1989. Phenelfamycins, a novel complex of elfamycin-type antibiotics. III. Activity in vitro and in a hamster colitis model. J. Antibiotics 42:94-101. (Pubitemid 19045383)
33. Therneau T, Grambsch P. 2000. Modeling survival data: extending the Cox model. Springer-Verlag, Berlin, Germany.
34. Therneau T, Grambsch P, Pankratz V. 2003. Penalized survival models and frailty. J. Comput. Graph. Stat. 12:156-175. (Pubitemid 36385268)